Clinical Research Directory

Inclusion Criteria: * 18 - 85 year old * Have a clinical diagnosis of stable non-segmental vitiligo * Depigmentation including at least 0.5% of the BSA on the face and neck * Previously treated with topical tacrolimus 0.1% BD for at least 3 months without significant response * Agree to stop using any topical treatments on face and neck and systemic treatment for vitiligo during the washout period until the trial concludes. Use of over-the-counter products approved by the investigator and camouflage makeup is allowed * Both male and female patients must commit to using effective birth control to prevent pregnancy or fathering a child throughout the study * Subjects or their legally authorized representative, if applicable, must be able to understand and willing to provide informed consent at Screening visit Exclusion Criteria: * Patients who refuse to give consent * Presence of different vitiligo types or other skin depigmentation conditions like piebaldism or leprosy, etc. * History of using depigmentation treatments other than hydroquinone for vitiligo or pigmentation issues * Any skin condition affecting study participation, active skin infections one week before the study starts, issues impacting vitiligo evaluation, or serious health problems limiting involvement or increasing risk * Significant medical disease that may hinder use of topical JAK inhibitor, e.g. serious infection, untreated chronic hepatitis, malignancy within 5 years except adequately treated non metastatic cancer, evidence of clinically significant or uncontrolled cardiovascular disease, thrombosis including DVT and PE, blood abnormality including significant thrombocytopenia, anaemia (Hb \<10g/dL) and significant neutropenia, substance misuse * Specific treatment use within certain periods before starting (Baseline visit): 1 week for topical vitiligo treatments 4 weeks for immunomodulators, photosensitizers, oral retinoids, methoxsalen, or live vaccines 8 weeks for laser or phototherapy on face and neck 12 weeks for biologics * Any prior application of topical or oral JAK inhibitors * Hemoglobin under 10 g/dL, significant liver dysfunction, and/or evidence of HIV infection or positive for HIV antibodies at initial screening or current acquired, common variable or inherited, primary or secondary immunodeficiency * Females of childbearing potential who are pregnant, during breastfeeding period, or those planning pregnancy during the study * Those unlikely or unable to comply with the requirements of this study protocol